Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report

Guangdie Yang; Jie Wang; Yinan Yao; Jun Zhao; Jun Zhao; Zheyan Yu; Qiqi Gao; Jiani Ye; Wenjiang Ma

doi:10.3389/fonc.2021.703318

Frontiers in Oncology (Jun 2021)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report

Guangdie Yang,
Jie Wang,
Yinan Yao,
Jun Zhao,
Jun Zhao,
Zheyan Yu,
Qiqi Gao,
Jiani Ye,
Wenjiang Ma

Affiliations

Guangdie Yang: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Jie Wang: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Yinan Yao: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Jun Zhao: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Jun Zhao: Department of Respiratory Medicine, Zhejiang Medical & Health Group Hangzhou Hospital, Hangzhou, China
Zheyan Yu: Department of Respiratory and Critical Care Medicine, Shengzhou People’s Hospital, Shaoxing, China
Qiqi Gao: Department of Pathology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Jiani Ye: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
Wenjiang Ma: Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

DOI: https://doi.org/10.3389/fonc.2021.703318
Journal volume & issue: Vol. 11

Abstract

Read online

ROS1 rearrangements have been identified as driver mutations, accounting for 1–2% of lung adenocarcinoma, but are extremely rare in case of lung squamous cell carcinoma. In this work, we report a lung squamous cell carcinoma in a patient with peripheral lung cancer radiological manifestation, harboring ROS1 rearrangement, with high sensitivity to crizotinib. Our findings suggest that clinicians should pay more attention toward the occurrence of ROS1 rearrangements and the application of crizotinib for lung squamous cell carcinoma treatment.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords